Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 2, 2024Cancer Research

Abstract PO1-15-05: Gene expression signature as a predictor of pathological complete response to neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab treatment in locally advanced HER2-positive breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJunghoon ShinJKJi‐Yeon KimECEun Yoon Cho

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shin et al. (2024) studied this question.

synapsesocial.com/papers/68e6be91b6db64358763e4e7https://doi.org/10.1158/1538-7445.sabcs23-po1-15-05
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PS4-04-01: A 15-Gene Predictive Signature for Pathologic Complete Response in Triple-Negative Breast Cancer: Validation Across Institutional and TCGA Cohorts2026
  2. 2Abstract PS09-01: Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group2024
  3. 3Abstract PS3-11-14: Impact of HER2 amplification and Estrogen Receptor Expression on Pathologic Complete Response to Dual Blockade in HER2-Positive Breast Cancer2026
  4. 4Abstract PO5-15-07: Integrative proteomics, phosphoproteomics, and RNA profiling revealed novel timeline-dependent vulnerabilities in HER2-positive breast cancer2024
  5. 5Abstract PO2-02-09: Pathological complete response to neoadjuvant systemic therapy and its predictive factors among early breast cancer subtypes: the emerging role of HER22024